NCT02822586
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
- Locations
-
- Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States
Clinical trial condition
Lymphoproliferative Disorders
Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.
10,082 public trials
2,050 recruiting studies
Lymphoproliferative Disorders trial results
Completed
Immunoablative Mini Transplant (Hematopoietic Peripheral Blood Stem Cell Transplant [HPBSC])
NCT00179764
- Conditions
- Bone Marrow Diseases, Chronic Disease, Disease Attributes, +33 more
- Locations
-
- Lurie Children's Hospital Chicago, Illinois, United States
NCT02453087
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
- City of Hope National Medical Center Duarte, California, United States
- Stanford Cancer Center Stanford, California, United States
- Medical Center of Aurora; Rocky Mountain Cancer Centers Aurora, Colorado, United States
- Georgetown University Medical Center Lombardi Cancer Center Washington D.C., District of Columbia, United States
NCT00169208
- Conditions
- Disease Attributes, Follicular Lymphoma, Hemic and Lymphatic Diseases, +12 more
- Locations
-
- Service de médecine D - Maladies du Sang CHU Angers Angers, France
- Service d'Hématologie Hôpital Jean Minjoz Besançon, France
- Hôpital Henri Mondor Créteil, France
- Hôpital A. Michallon BP 217X Grenoble, France
NCT00770224
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +7 more
- Locations
-
- Providence Cancer Center at Providence Hospital Mobile, Alabama, United States
- Arizona Cancer Center at University of Arizona Health Sciences Center Tucson, Arizona, United States
- Saint Anthony's Hospital at Saint Anthony's Health Center Alton, Illinois, United States
- Cancer Care Center of Decatur Decatur, Illinois, United States
Completed
Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma
NCT01447914
- Conditions
- Amyloidosis, Anemia, Blood Protein Disorders, +38 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT00137995
- Conditions
- Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
- Locations
-
- Memorial Sloan Kettering Cancer Center New York, United States
- Australian leukemia and lymphoma group Sydney, Australia
- Groupe d'atude des lymphome de l'adulte Yvoir, Belgium
- Czech Lymphoma study group Prague, Czechia
NCT01818752
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
- Locations
-
- California Cancer Associates for Research & Excellence, Inc. (cCARE) Fresno, California, United States
- Marin Cancer Care Greenbrae, California, United States
- Sutter Gould Medical Foundation Modesto, California, United States
- Innovative Clinical Research Institute Whittier, California, United States
NCT03048097
- Conditions
- Hemic and Lymphatic Diseases, Hypersensitivity, Hypersensitivity, Delayed, +4 more
- Locations
-
- Yale New Haven Hospital New Haven, Connecticut, United States
NCT01087424
- Conditions
- Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
- Locations
-
Not specified